Skin Diseases, Bacterial clinical trials
The registry lists 37 studies for Skin Diseases, Bacterial across more than 10 countries. 2 are recruiting or about to start. 17 of them are mainly about Skin Diseases, Bacterial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 3 narrower conditions too, such as Hidradenitis Suppurativa: 368 studies, 90 open.
Get an email when these change. Save the Skin Diseases, Bacterial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
MoonLake Immunotherapeutics AG (5) · Melinta Therapeutics, Inc. (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Ole Hyldegaard (2) · Forest Laboratories (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Basilea Pharmaceutica (2) · Arrevus Inc. (1)
What is being tested here
Drugs under test in Skin Diseases, Bacterial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 1 Skin Diseases, Bacterial studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 37 studies, recruiting or not: 22% stop at 75 or younger and 16% at 65; 22% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 37 of 37. search them.
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaEnrolling by invitationNCT07007637Phase 316 countries
- Fosfomycin I.v. for Treatment of Severely Infected PatientsRecruitingNCT029799515 countries
- An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)CompletedNCT06768671Phase 31 country
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseActive, not recruitingNCT06993610Phase 26 countries
- Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin InfectionsCompletedNCT00368537Phase 412 countries
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaCompletedNCT05322473Phase 27 countries
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT06411899Phase 310 countries
- Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT06411379Phase 312 countries
- Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure InfectionCompletedNCT02925416Phase 41 country
- Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionCompletedNCT03747497Phase 21 country
- Dalbavancin in Real Clinical Practice in SpainCompletedNCT044856761 country
- Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)CompletedNCT03716024Phase 21 country
- Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure InfectionsCompletedNCT00761215Phase 21 country
- Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin InfectionsTerminatedNCT01619410Not applicable1 country
- Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)CompletedNCT02276482Phase 3
- Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort StudyCompletedNCT031473521 country
- Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin InfectionsCompletedNCT00948142Phase 21 country
- Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01984684Phase 316 countries
- Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01811732Phase 37 countries
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsCompletedNCT00424190Phase 311 countries
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsCompletedNCT00423657Phase 312 countries
- Biomarkers in Patients With Flesh-eating Bacterial InfectionsCompletedNCT021809061 country
- Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical DrainageCompletedNCT02024867Not applicable1 country
- A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)CompletedNCT02477514Phase 1
- Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin InfectionsCompletedNCT00719810Phase 22 countries
- Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin InfectionsCompletedNCT00646958Phase 21 country
- Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in RussiaCompletedNCT017008421 country
- Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical ValidationWithdrawnNCT01551719Not applicable1 country
- Avelox in Complicated Skin and Skin Structure InfectionsCompletedNCT0099799712 countries
- Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of AgeCompletedNCT00488345Phase 26 countries
- Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure InfectionsCompletedNCT00228982Phase 3
- Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure InfectionsCompletedNCT00210899Phase 3
- A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the SkinCompletedNCT00257062Phase 3
- A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the SkinCompletedNCT00257036Phase 2/3
- A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin InfectionsCompletedNCT00249197Phase 3
- Simple Hygiene Versus Alcohol Based Usual Care for Umbilical CordStatus unknownNCT01369251Phase 31 country
- Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)CompletedNCT00303550Phase 31 country